Erratum: Development of angiotensin IV analogs as hepatocyte growth factor/met modifiers (Journal of Pharmacology and Experimental Therapeutics (2012) 340 (539-548) DOI: 10.1124/jpet.111.188136);Development of angiotensin IV analogs as hepatocyte growth factor/met modifiers

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 539-548

  Kawas, Leen H ^a   McCoy, Alene T ^a   Yamamoto, Brent J ^a   Wright, John W ^a   Harding, Joseph W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II [3-8]; NORLEUAL; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; EMBRYO; HINGE REGION; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

EID: 84857282811     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.188136concern     Document Type: Erratum

References (39)

1. Barkmeier AJ and Carvounis PE (2011) Retinal pigment epithelial tears and the management of exudative age-related macular degeneration. Semin Ophthalmol 26:94-103.
2. Birchmeier C, Birchmeier W, Gherardi E, and Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640)
3. Borowiak M, Garratt AN, Wüstefeld T, Strehle M, Trautwein C, and Birchmeier C (2004) Met provides essential signals for liver regeneration. Proc Nat Acad Sci 101:10608-10613. (Pubitemid 38955789)
4. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, et al. (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Metdependent human tumors. Cancer Res 66:1721-1729. (Pubitemid 43259957)
5. Canavese M, Altruda F, Ruzicka T, and Schauber J (2010) Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis - a possible target for novel therapies? J Dermatol Sci 58:171-176.
6. Chirgadze DY, Hepple JP, Zhou H, Byrd RA, Blundell TL, and Gherardi E (1999) Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 6:72-79. (Pubitemid 29232427)
7. Christensen JG, Burrows J, and Salgia R (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1-26. (Pubitemid 40732764)
8. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355. (Pubitemid 37413476)
9. Comoglio PM, Giordano S, and Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516. (Pubitemid 351767118)
10. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, and Van Vlierberghe H (2011) Angiogenesis in chronic liver disease and its complications. Liver Int 31:146-162.
11. Daquinag AC, Zhang Y, and Kolonin MG (2011) Vascular targeting of adipose tissue as an anti-obesity approach. Trends Pharmacol Sci 32:300-307.
12. Donate LE, Gherardi E, Srinivasan N, Sowdhamini R, Aparicio S, and Blundell TL (1994) Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci 3:2378-2394.
13. Eder JP, Vande Woude GF, Boerner SA, and LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214.
14. Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, and Galeotti T (2006) Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 25:3689-3698. (Pubitemid 43980490)
15. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, et al. (2006) Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Nat Acad Sci 103:4046-4051.
16. Halaban R, Rubin JS, Funasaka Y, Cobb M, Boulton T, Faletto D, Rosen E, Chan A, Yoko K, and White W (1992) Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 7:2195-2206.
17. Hansel TT, Kropshofer H, Singer T, Mitchell JA, and George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325-338.
18. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
19. Jeganathan VS (2011) Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol 12:369-372.
20. Kakazu A, Chandrasekher G, and Bazan HE (2004) HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway. Invest Ophthalmol Vis Sci 45:3485-3492. (Pubitemid 39298566)
21. Kanda S, Kanetake H, and Miyata Y (2006) HGF-induced capillary morphogenesis of endothelial cells is regulated by Src. Biochem Biophys Res Commun 344:617-622.
22. Kawas LH, Yamamoto BJ, Wright JW, and Harding JW (2011) Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity. J Pharmacol Exp Ther 339:509-518.
23. Liu X, Newton RC, and Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37-45.
24. Liu X, Yao W, Newton RC, and Scherle PA (2008) Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17:997-1011.
25. Lokker NA, Mark MR, Luis EA, Bennett GL, Robbins KA, Baker JB, and Godowski PJ (1992) Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 11:2503-2510.
26. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, and Lamszus K (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152. (Pubitemid 44703780)
27. Maya BL (2010) Endocrine side effects of broad-acting kinase inhibitors. Endocr Related Cancer 17:R233-R244.
28. Morotti A, Mila S, Accornero P, Tagliabue E, and Ponzetto C (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21:4885-4893.
29. Ratajczak MZ, Marlicz W, Ratajczak J, Wasik M, Machalinski B, Carter A, and Gewirtz AM (1997) Effect of hepatocyte growth factor on early human haemopoietic cell development. Br J Haematol 99:228-236. (Pubitemid 27461354)
30. Sardinia MF, Hanesworth JM, Krishnan F, and Harding JW (1994) AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 15:1399-1406. (Pubitemid 24381186)
31. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, et al. (2003) A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63:5462-5469. (Pubitemid 37139865)
32. Sheth PR, Hays JL, Elferink LA, and Watowich SJ (2008) Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. Biochemistry 47:4028-4038. (Pubitemid 351458117)
33. Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, et al. (2008) Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 7:1913-1922.
34. Stella MC and Comoglio PM (1999) HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357-1362.
35. Thompson J, Dolcet X, Hilton M, Tolcos M, and Davies AM (2004) HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol Cell Neurosci 27:441-452. (Pubitemid 39539998)
36. Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, and Harding JW (2010) The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther 333:161-173.
37. You WK and McDonald DM (2008) The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41:833-839.
38. Youles M, Holmes O, Petoukhov MV, Nessen MA, Stivala S, Svergun DI, and Gherardi E (2008) Engineering the NK1 fragment of hepatocyte growth factor/ scatter factor as a MET receptor antagonist. J Mol Biol 377:616-622.
39. Zhang YW and Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408-417.